ASH 2023 | AML2012 trial: daunorubicin-based induction therapies in pediatric AML
Gertjan Kaspers, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, discusses a randomized comparison using data from the Phase III AML2012 trial (NCT01828489), which compared a combination of the anthracycline antibiotic daunorubicin with low-dose cytarabine and etoposide against a combination of daunorubicin with high-dose cytarabine and fludarabine as induction treatment for pediatric acute myeloid leukemia (AML). Measurable residual disease (MRD)-based risk stratification was utilized, and survival outcomes were similar between the two treatment regimens. However, the combination of daunorubicin with high-dose cytarabine and fludarabine conferred greater toxicity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
